Biotech | December 15, 2021
Aragen Life Sciences acquires Intox
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
FDA changes inspection classification of the facility to Voluntary Action Indicated
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
The total cost of the project is estimated at Rs 30 crore
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19
Subscribe To Our Newsletter & Stay Updated
